Liminatus Pharma, Inc. (LIMN) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US53271X1081

Price
2.77 USD
Market cap
3.72 m USD
P/E (2025)
–
P/S (2025)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
103.99 %
Return on assets (ROA)
-1,990.37 %

Liminatus Pharma, Inc. financials

Fiscal year20242025
Operating income-3.33 m USD-2.97 m USD
EBIT-3.33 m USD-10.07 m USD
Net income-3.55 m USD-10.21 m USD
Diluted EPS – continuing operations-0.20 USD-0.43 USD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Liminatus Pharma, Inc.

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.